News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Citi Rates CCB (00939.HK) at Buy on Attractive Valuation
CCB (00939.HK) recorded a 13% YoY increase in pre-provision operating profit (PPOP) in 1Q26, accelerating from 5% in 4Q25, driven by a rebound in net interest margin (NIM), strong ...
Reset
Send
The window will close in 5 seconds
<Research>Citi Rates CCB (00939.HK) at Buy on Attractive Valuation
Close
Recommend
15
Positive
12
Negative
8
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

CCB (00939.HK)  -0.210 (-2.336%)    Short selling $1.17B; Ratio 31.007%   recorded a 13% YoY increase in pre-provision operating profit (PPOP) in 1Q26, accelerating from 5% in 4Q25, driven by a rebound in net interest margin (NIM), strong trading gains, decent fee income and improvement in the cost-to-income ratio (CIR), Citi Research issued a research report saying.

Citi Research believed that CCB's 1Q26 PPOP will beat its expectation, while earnings growth was in line with forecast, ranking second and third respectively among large banks.

Related News CCB (00939.HK) 1Q26 Net Profit Up 3.5% YoY to RMB86.291 billion
The broker was encouraged by the significant rebound in CCB's NIM, and believed that its valuation is attractive. Therefore, Citi Research rated CCB's H-shares at Buy, with a target price of $9.88.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-30 16:25.)

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.